Project description:Genome-wide gene expression analysis of murine splenic B-cells following retroviral transduction with a constitutively active IRF5 (IRF5-4D)
Project description:Genome-wide gene expression analysis of murine splenic B-cells following retroviral transduction with a constitutively active IRF5 (IRF5-4D) Illumina WG-6 v2.0 arrays were hybridized to determine the gene expression profile of murine splenic B-cells following retroviral transduction with i) control virus (MSCV-IRES-CFP) or ii) IRF5-4D virus (MSCV-IRF5-4D-CFP). All hybridizations were done in biological triplicates.
Project description:Genome-wide gene expression analysis of Reh cells following transfection with constitutively active IRF5-4D, constitutively active IKKβ(EE), or both in combination. Affymetrix U133 Plus 2.0 oligonucleotide arrays were hybridized to determine the gene expression profile of acute lymphoblastic leukemia-derived Reh cells following transfection with i) control constructs, ii), a constitutively active variant of IRF5 (IRF5-4D), iii) a constitutively active variant of the IkB kinase β (IKKβ(EE)), or iv) IRF5-4D in combination with IKKβ(EE). All hybridizations were done in biological duplicates.
Project description:Genome-wide gene expression analysis of Reh cells following transfection with constitutively active IRF5-4D, constitutively active IKKβ(EE), or both in combination.
Project description:Expression analysis of Reh cells after transfection with constitutively active variants of IRF5 (IRF5-4D) and/or constitutively active IKKβ(EE)
Project description:The establishment of a murine disease model of MLL-AF4 via retroviral transduction has been difficult due to a lack of understanding of its unknown regulatory mechanisms. We showed that MLL-AF4 protein is post-transcriptionally regulated, and its synonymous mutant is able to induce myeloid leukemia by retroviral transduction. To validate synonymous mutant of MLL-AF4 is phenotypically similar to the MLL-mAf4, we analyzed the gene expression profiles by RNA-seq.
